UCB to Present Myasthenia Gravis Data, Including Early Cizutamig Results, at AANEM 2026

Key Takeaways

• UCB is presenting data from its generalized myasthenia gravis (gMG) portfolio at the AANEM Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session, September 29 to October 2 in Orlando, Florida.
• The abstracts cover minimal symptom expression (MSE) as a treatment goal, the burden of ocular MG, and social risks for Black patients with gMG despite high socioeconomic resources.
• UCB will also present interim Phase 1b data on cizutamig, an investigational BCMA×CD3 T-cell engager the company acquired through Candid Therapeutics. Cizutamig is not approved by the FDA or any other health authority.

UCB, a global biopharmaceutical company focused on severe diseases of the immune system and central nervous system, announced it is presenting real-world and clinical data from its gMG portfolio at this year's AANEM Annual Meeting and MGFA Scientific Session.

A focus of the new data is MSE, which UCB describes as an increasingly important treatment goal. Two post hoc analyses look at how patients reach it. The first examines baseline Myasthenia Gravis Activities of Daily Living (MG-ADL) scores in adults with gMG treated with zilucoplan for up to 120 weeks, grouped by whether they achieved MSE, defined as an MG-ADL score of 0 or 1 without rescue therapy. It also looks at the time to MSE after starting zilucoplan. The second looks at the proportion of patients who reached MSE at any point during treatment with rozanolixizumab, or during observation in a symptom-driven cycle, through Cycle 13, based on whether they reached MSE in Cycle 1.

Other abstracts address the burden and unmet needs of people living with ocular MG and the ocular symptoms of gMG. One examines why harmful social risks relevant to neuromuscular health outcomes may persist for Black patients with gMG despite high socioeconomic resources.

UCB will also share interim data from a Phase 1b dose-escalation and dose-expansion study of cizutamig, an investigational BCMA×CD3 T-cell engager. Cizutamig is designed to reduce autoantibodies by depleting B cells, plasma cells, and plasmablasts, while aiming to minimize cytokine release syndrome. UCB gained the drug through its acquisition of Candid Therapeutics. The company notes that cizutamig's safety and efficacy have not been established.